Dapagliflozin 5 Mg

You may take this medicine with or without food.

Store the medicine in a closed container at room temperature, away from heat, moisture, and direct light.

side effects may include nasopharyngitis, back pain, increased urination, nausea, and constipation.

Avoid use of this drug during pregnancy and prescribe an alternative. Evidence has demonstrated fetal abnormalities or risks when used during pregnancy. Evidence and/or expert consensus has demonstrated harmful infant effects when used during breastfeeding.

Avoid alcohol and tobaccco consumption while taking this medicnes. Dizziness, lightheadedness, or fainting may occur with this medicine. Drink plenty of water during exercise or in hot weather. Check with your doctor if you have severe nausea, vomiting, or diarrhea that does not stop. This may cause you to lose too much water. This medicine may cause hypoglycemia (low blood sugar). This is more common when this medicine is taken together with other diabetes medicines (eg, insulin, glipizide, or glyburide). The symptoms of low blood sugar must be treated before they cause you to pass out. People feel different symptoms with low blood sugar. Some symptoms of low blood sugar include: behavior changes that are similar to being drunk, blurred vision, cold sweats, confusion, difficulty with thinking, drowsiness, excessive hunger, fast heartbeat, headaches that continue, nausea, shakiness, slurred speech, or unusual tiredness or weakness. Talk to your doctor about how to treat low blood sugar. If you become pregnant while taking dapagliflozin, your doctor may switch you to another medicine to control your blood sugar. Talk to your doctor about the best way to control your blood sugar if you plan to become pregnant or while you are pregnant.

Product Information: FORXIGA(R) oral tablets, dapagliflozin oral tablets. AstraZeneca Pharmaceuticals LP (per manufacturer), Wilmington, DE, 2021. Dandona P, Mathieu C, Phillip M, et al: Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol 2017; 5(11):864-876.

Dapagliflozin inhibits sodium-glucose cotransporter 2 (SGLT2), thereby reducing reabsorption of filtered glucose and promoting urinary glucose excretion. Decreased sodium reabsorption and increased delivery of sodium to the distal tubule also occur. Several physiological functions may be influenced, including decreased intraglomerular pressure (believed to be mediated by increased tubuloglomerular feedback) and lowering of both pre- and afterload of the heart and downregulation of sympathetic activity .

Anti Diabetic